B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
-5.05%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
-$155M
(-4.4%)
Cap. Flow
-$860M
Cap. Flow
% of AUM
-25.49%
Top 10 Holdings %
Top 10 Hldgs %
37.46%
Holding
92
New
13
Increased
23
Reduced
14
Closed
19
Avg Time Held
1
year
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Transmedics
TMDX
|
+$85.8M |
| 2 |
Keros Therapeutics
KROS
|
+$61.7M |
| 3 |
Legend Biotech
LEGN
|
+$59.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$49.3M |
| 5 |
Geron
GERN
|
+$28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Penumbra
PEN
|
+$40.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$39M |
| 3 |
Arvinas
ARVN
|
+$31.6M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$30.9M |
| 5 |
DexCom
DXCM
|
+$29.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.36% |
| 2 | Miscellaneous | 33.64% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
4D Molecular Therapeutics
FDMT
$675M
| $6.83M | 0.2% |
1,225,448
| – | – |
2024 Q1
3 quarters
|
|
52
DELISTED
NEVRO CORP.
NVRO
| $6.32M | 0.19% |
1,698,768
| – | – |
2022 Q4
8 quarters
|
|
53
Zura Bio
ZURA
$428M
| $6.18M | 0.18% |
2,472,806
| – | – |
2024 Q3
1 quarter
|
|
54
CeriBell Inc
CBLL
$1.01B
| $5.43M | 0.16% |
+210,000
| New | +$5.72M |
2024 Q4
0 quarters
|
|
55
Pulmonx
LUNG
$76.4M
| $5.11M | 0.15% |
752,541
| – | – |
2022 Q4
8 quarters
|
|
56
Jade Biosciences
JBIO
$848M
| $3.82M | 0.11% |
+41,157
| New | +$3.55M |
2024 Q4
0 quarters
|
|
57
Skye Bioscience
SKYE
$6.73M
| $2.34M | 0.07% |
+103,217
| New | +$3.45M |
2024 Q4
0 quarters
|
|
58
Protagonist Therapeutics
PTGX
$8.86B
| $776K | 0.02% |
+20,109
| New | +$877K |
2024 Q4
0 quarters
|
|
59
Viridian Therapeutics
VRDN
$2.1B
| $654K | 0.02% |
+34,094
| New | +$741K |
2024 Q4
0 quarters
|
|
60
Alector
ALEC
$203M
| – | – |
-2,158,245
| Closed | -$10.1M | – |
|
|
61
Arvinas
ARVN
$449M
| – | – |
-1,284,472
| Closed | -$31.6M | – |
|
62
BridgeBio Pharma
BBIO
$12.7B
| – | – |
-298,400
| Closed | -$7.6M | – |
|
63
Boston Scientific
BSX
$61.4B
| – | – |
-189,200
| Closed | -$15.9M | – |
|
64
Castle Biosciences
CSTL
$1.01B
| – | – |
-331,986
| Closed | -$9.47M | – |
|
65
DBV Technologies S.A. American Depositary Shares
DBVT
$562M
| – | – |
-326,108
| Closed | -$1.14M | – |
|
|
66
DexCom
DXCM
$31.6B
| – | – |
-441,086
| Closed | -$29.6M | – |
|
67
DELISTED
Elevation Oncology
ELEV
| – | – |
-473,503
| Closed | -$284K | – |
|
68
Fulcrum Therapeutics
FULC
$281M
| – | – |
-1,069,158
| Closed | -$3.82M | – |
|
69
DELISTED
HilleVax
HLVX
| – | – |
-1,064,000
| Closed | -$1.87M | – |
|
70
Iovance Biotherapeutics
IOVA
$6.52B
| – | – |
-217,928
| Closed | -$2.05M | – |
|
71
Lexeo Therapeutics
LXEO
$218M
| – | – |
-728,777
| Closed | -$6.59M | – |
|
72
Lexicon Pharmaceuticals
LXRX
$716M
| – | – |
-801,584
| Closed | -$1.26M | – |
|
|
73
Madrigal Pharmaceuticals
MDGL
$10.6B
| – | – |
-183,818
| Closed | -$39M | – |
|
74
Ocular Therapeutix
OCUL
$1.59B
| – | – |
-2,239,770
| Closed | -$19.5M | – |
|
75
Insulet
PODD
$9.31B
| – | – |
-42,500
| Closed | -$9.89M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q4 2024 Portfolio in Review
As of Q4 2024, Braidwell held 92 positions worth $3.37B, down 4.4% from $3.53B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Braidwell withdrew a net $860M in Q4 2024, closing 19 positions and reducing 14 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $39M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Braidwell opened a new position in Transmedics worth $57.5M.
- Braidwell's largest Q4 2024 buy was Transmedics: 922,100 shares worth $57.5M.
- Braidwell added most to Keros Therapeutics in Q4 2024, an estimated $61.7M increase.
- Braidwell's biggest Q4 2024 reduction was Penumbra, cutting an estimated $40.4M.
- Braidwell fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $39M.
- Braidwell's ten largest holdings make up 37% of its $3.37B portfolio in Q4 2024.
- Braidwell opened 13 new positions and closed 19 in Q4 2024.
- Braidwell's portfolio value fell 4.4% quarter-over-quarter to $3.37B.
Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.